These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lenacapavir (Sunlenca) for multidrug-resistant HIV. Med Lett Drugs Ther; 2023 May; 65(1675):68-70. PubMed ID: 37155250 [No Abstract] [Full Text] [Related]
3. Lenacapavir: A novel injectable HIV-1 capsid inhibitor. Hitchcock AM; Kufel WD; Dwyer KAM; Sidman EF Int J Antimicrob Agents; 2024 Jan; 63(1):107009. PubMed ID: 37844807 [TBL] [Abstract][Full Text] [Related]
4. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Gupta SK; Berhe M; Crofoot G; Benson P; Ramgopal M; Sims J; McDonald C; Ruane P; Sanchez WE; Scribner A; Liu SY; VanderVeen LA; Dvory-Sobol H; Rhee MS; Baeten JM; Koenig E Lancet HIV; 2023 Jan; 10(1):e15-e23. PubMed ID: 36566079 [TBL] [Abstract][Full Text] [Related]
5. Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV. Prather C; Lee A; Yen C Am J Health Syst Pharm; 2023 Dec; 80(24):1774-1780. PubMed ID: 37767713 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial. Ogbuagu O; Segal-Maurer S; Ratanasuwan W; Avihingsanon A; Brinson C; Workowski K; Antinori A; Yazdanpanah Y; Trottier B; Wang H; Margot N; Dvory-Sobol H; Rhee MS; Baeten JM; Molina JM; Lancet HIV; 2023 Aug; 10(8):e497-e505. PubMed ID: 37451297 [TBL] [Abstract][Full Text] [Related]
7. Lenacapavir: an attractive option, but proceed with caution. Harris M Lancet HIV; 2023 Aug; 10(8):e486-e487. PubMed ID: 37451298 [No Abstract] [Full Text] [Related]
8. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Dvory-Sobol H; Shaik N; Callebaut C; Rhee MS Curr Opin HIV AIDS; 2022 Jan; 17(1):15-21. PubMed ID: 34871187 [TBL] [Abstract][Full Text] [Related]
9. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options. Tuan J; Ogbuagu O Expert Rev Anti Infect Ther; 2023 Jun; 21(6):565-570. PubMed ID: 37067160 [TBL] [Abstract][Full Text] [Related]
10. Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus. Lee NE; Sutherland RK Curr Opin Infect Dis; 2023 Feb; 36(1):15-19. PubMed ID: 36753704 [TBL] [Abstract][Full Text] [Related]
11. Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV. Tailor MW; Chahine EB; Koren D; Sherman EM Ann Pharmacother; 2024 Feb; 58(2):185-195. PubMed ID: 37138515 [TBL] [Abstract][Full Text] [Related]
13. Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method for quantifying lenacapavir plasma concentrations: Application to therapeutic monitoring. West RE; Oberly PJ; Riddler SA; Nolin TD; Devanathan AS J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Nov; 1230():123905. PubMed ID: 37866010 [TBL] [Abstract][Full Text] [Related]